Camidanlumab tesirine

Indicated For

Relapsed or refractory classic Hodgkin lymphoma

About This Medication

# Advancing Patient Support Program Patient Guide: How to Get Camidanlumab Tesirine at Low or No Cost Camidanlumab tesirine (Cami) is an investigational antibody-drug conjugate developed by ADC Therapeutics for treating relapsed or refractory classical Hodgkin lymphoma (cHL), but it is not yet FDA-approved, and no active patient assistance program exists as of now. This guide provides general information on typical prescription assistance programs (PAPs) while noting the current status of Cami; always consult your healthcare provider for the latest updates. ## About Camidanlumab Tesirine (Cami) **Camidanlumab tesirine** is an anti-CD25 antibody-drug conjugate designed to target cancer cells in patients with relapsed or refractory cHL, a type of lymphoma that returns or doesn't respond to standard treatments.[1][3][7] In clinical trials, such as the Phase 2 ADCT-301-201 study, Cami showed promising results: an overall response rate of 70% and complete response rate of 33% in heavily pretreated patients who had failed brentuximab vedotin and PD-1 inhibitors like nivolumab or pembrolizumab.[3][4][7] Patients received it intravenously every 3 weeks at doses starting at 45 μg/kg for the first two cycles, then 30 μg/kg, up to 1 year or longer if benefiting.[7] The drug links a monoclonal antibody to a potent pyrrolobenzodiazepine (PBD) dimer payload, delivering chemotherapy directly to CD25-expressing lymphoma cells while sparing healthy tissue.[4] Median duration of response was 13.7 months, and progression-free survival was 9.1 months in trials.[4][6] Common side effects included treatment-emergent adverse events (TEAEs) leading to dose adjustments in 56% of patients and discontinuation in 27%, with serious events in 39%.[4] Premedication with dexamethasone helps manage toxicities.[7] However, ADC Therapeutics paused its Biologics License Application (BLA) in 2022 after FDA feedback requiring a Phase 3 trial before accelerated approval, delaying commercialization.[5][6] As of 2026, Cami remains in clinical development, with no approved commercial product or standard PAP.[1][5] Expanded access or compassionate use may be options via your doctor—contact ADC Therapeutics directly.[5] ## Who Qualifies for Patient Assistance? Since Cami lacks an FDA approval and dedicated PAP like the "Advancing Patient Support Program," eligibility follows general PAP models from manufacturers. Typically, programs help uninsured or underinsured patients with household incomes at or below 400-500% of the Federal Poverty Level (FPL). For a family of 4 in 2026, this might mean under $120,000-$150,000 annually, but exact thresholds vary. Qualification often requires: - U.S. residency and valid prescription. - Diagnosis of relapsed/refractory cHL after ≥3 prior therapies.[7] - No adequate insurance coverage. If approved in the future, expect similar criteria. Check ADC Therapeutics' website or call their support line for updates. ## Income Eligibility Breakdown Most PAPs use FPL guidelines. Here's a sample table based on standard U.S. programs (2026 estimates; actuals unpublished for this program): | Household Size | 400% FPL (Approx. Annual Income) | 500% FPL (Approx. Annual Income) | |---------------|---------------------------------|---------------------------------| | 1 | $60,000 | $75,000 | | 2 | $81,000 | $101,250 | | 3 | $102,000 | $127,500 | | 4 | $123,000 | $153,750 | | +1 person | +$21,000 | +$26,250 | *Note: Thresholds are null for this program; this is illustrative. Verify with manufacturer.*[1] ## Insurance Requirements PAPs usually require commercial insurance but exclude government plans like Medicare, Medicaid, or VA. Patients on Medicare Part D may face coverage gaps; PAPs often cover copays up to a cap (e.g., $5,000/year). No Medicare patients typically, but bridge programs exist. Submit proof of denial or high copays. Details null here—contact insurer first.[1] ## Step-by-Step Application Process 1. **Confirm Eligibility**: Discuss with your oncologist if Cami is appropriate via trial or expanded access.[2][5] 2. **Gather Documents**: Prescription, proof of income (tax returns, pay stubs), insurance denial, ID.[1] 3. **Apply**: Online, phone, or mail (details null; visit ADC Therapeutics site or call patient services).[1] 4. **Submit**: Include doctor's signature and diagnosis.[7] 5. **Follow Up**: Track status weekly. For investigational drugs, apply through clinicaltrials.gov or manufacturer compassionate use.[2] ## Timeline and Delivery Standard PAP processing: 2-4 weeks. Delivery via mail or pharmacy in 7-10 days. Refills auto-ship monthly. Processing time null here; expect delays for unapproved drugs.[1][4] ## Alternatives if Denied or Ineligible - **Clinical Trials**: Enroll via clinicaltrials.gov (e.g., NCT02432235).[2] - **Other PAPs**: NeedyMeds, PAN Foundation for lymphoma costs. - **Financial Aid**: Co-pay cards, 340B clinics, generic alternatives. - **Competing Treatments**: Brentuximab vedotin, PD-1 inhibitors, or bispecifics for R/R cHL. No biosimilars for Cami.[1] ## Disclaimer This guide is educational, not medical/financial advice. Cami is investigational; no PAP confirmed. Consult healthcare provider, ADC Therapeutics, or social worker. Info based on trials up to 2025; status may change.[1][6][7] Word count: 942.

Program information last verified: March 30, 2026